Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPT-300 monotherapy versus placebo for major depressive disorder
2025-521240-37-00Phase 2Authorised
- Sponsor
- Seaport Therapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing BREXANOLONE CAPRILCERBATE monotherapy with Placebo monotherapy (2 arms). Primary endpoint: Change from baseline to Visit 8 (Study Day 42) in Hamilton Depression Rating Scale-17 total score. Planned start Sep 2025; status: authorised.
02
Drugs
brexanolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-521240-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521240-37-00.